| Primary |
| Hypertension |
29.4% |
| Intentional Overdose |
23.5% |
| Heart Rate Increased |
11.8% |
| Poisoning Deliberate |
11.8% |
| Postural Orthostatic Tachycardia Syndrome |
11.8% |
| Hyperlipidaemia |
5.9% |
| Supraventricular Tachycardia |
5.9% |
|
| Ventricular Hypokinesia |
33.3% |
| Nausea |
11.1% |
| Product Friable |
11.1% |
| Product Quality Issue |
11.1% |
| Sinus Arrest |
11.1% |
| Visual Disturbance |
11.1% |
| Weight Decreased |
11.1% |
|
| Secondary |
| Hypertension |
25.5% |
| Drug Use For Unknown Indication |
20.2% |
| Product Used For Unknown Indication |
9.6% |
| Cardiogenic Shock |
8.5% |
| Cardiac Failure Congestive |
6.4% |
| Glaucoma |
6.4% |
| Osteoporosis |
6.4% |
| Ocular Hypertension |
5.3% |
| Hypercholesterolaemia |
3.2% |
| Intentional Overdose |
3.2% |
| Benign Neoplasm Of Prostate |
1.1% |
| Dyslipidaemia |
1.1% |
| Hyperuricaemia |
1.1% |
| Immunosuppression |
1.1% |
| Macular Oedema |
1.1% |
|
| Wheezing |
14.3% |
| Coma |
9.5% |
| Multiple Drug Overdose |
9.5% |
| Pulmonary Oedema |
9.5% |
| Aortic Dissection |
4.8% |
| Bradycardia |
4.8% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
4.8% |
| Intentional Overdose |
4.8% |
| Ocular Hypertension |
4.8% |
| Overdose |
4.8% |
| Pulmonary Haemorrhage |
4.8% |
| Rash |
4.8% |
| Sexual Dysfunction |
4.8% |
| Staphylococcal Infection |
4.8% |
| Ventricular Hypokinesia |
4.8% |
| Vision Blurred |
4.8% |
|
| Concomitant |
| Product Used For Unknown Indication |
31.8% |
| Hypertension |
17.3% |
| Drug Use For Unknown Indication |
7.7% |
| Rheumatoid Arthritis |
7.1% |
| Acute Coronary Syndrome |
4.6% |
| Acute Myeloid Leukaemia |
3.1% |
| Prophylaxis |
3.1% |
| Diffuse Large B-cell Lymphoma |
2.8% |
| Diabetes Mellitus |
2.6% |
| Atrial Fibrillation |
2.3% |
| Multiple Myeloma |
2.2% |
| Myocardial Infarction |
2.2% |
| Glaucoma |
2.0% |
| Arrhythmia |
1.7% |
| Blood Cholesterol Increased |
1.7% |
| Osteoporosis |
1.7% |
| Depression |
1.5% |
| Hypercholesterolaemia |
1.5% |
| Hyperlipidaemia |
1.5% |
| Perioperative Analgesia |
1.5% |
|
| Weight Decreased |
8.1% |
| Pyrexia |
7.0% |
| Thrombocytopenia |
7.0% |
| Vomiting |
7.0% |
| Diarrhoea |
5.8% |
| Hepatic Enzyme Increased |
5.8% |
| Septic Shock |
5.8% |
| Drug Interaction |
4.7% |
| Facial Palsy |
4.7% |
| Glioblastoma Multiforme |
4.7% |
| Hepatic Encephalopathy |
4.7% |
| Hepatic Failure |
4.7% |
| Sepsis |
4.7% |
| Therapy Regimen Changed |
4.7% |
| Cardiac Failure |
3.5% |
| Cytolytic Hepatitis |
3.5% |
| Hyponatraemia |
3.5% |
| Insomnia |
3.5% |
| Jaundice Cholestatic |
3.5% |
| Myalgia |
3.5% |
|
| Interacting |
|
| Atrioventricular Block Second Degree |
66.7% |
| Arrhythmia |
33.3% |
|
